Your browser doesn't support javascript.
loading
Treatment strategies for hypertension in patients with type 1 diabetes.
Katsimardou, Alexandra; Imprialos, Konstantinos; Stavropoulos, Konstantinos; Sachinidis, Alexandros; Doumas, Michalis; Athyros, Vasilios G.
Afiliação
  • Katsimardou A; Department of Internal Medicine, Aristotle University , Thessaloniki, Greece.
  • Imprialos K; Department of Internal Medicine, Aristotle University , Thessaloniki, Greece.
  • Stavropoulos K; Department of Internal Medicine, Aristotle University , Thessaloniki, Greece.
  • Sachinidis A; Department of Internal Medicine, Aristotle University , Thessaloniki, Greece.
  • Doumas M; Department of Internal Medicine, Aristotle University , Thessaloniki, Greece.
  • Athyros VG; Department of Internal Medicine, Aristotle University , Thessaloniki, Greece.
Expert Opin Pharmacother ; 21(10): 1241-1252, 2020 Jul.
Article em En | MEDLINE | ID: mdl-32066278
ABSTRACT

INTRODUCTION:

Type 1 diabetes mellitus (T1DM) is a chronic, autoimmune disease that is characterized by total absence of insulin production. Hypertension is a common comorbidity in T1DM with complex pathophysiology, while it is also a well-recognized risk factor for the development of cardiovascular disease (CVD), as well as other microvascular diabetic complications. AREAS COVERED The purpose of this review is to present the current definitions, epidemiological data and prevalence rates of hypertension in T1DM, as well as to describe current therapeutic options. EXPERT OPINION Hypertension affects around a third of the type 1 diabetic population, with higher prevalence rates in older individuals with longer disease duration. Although hypertension affects a substantial proportion of T1DM individuals, blood pressure control rates are disappointingly low. Alongside lifestyle modification, antihypertensive treatment should be initiated in those with blood pressure above 140/90 mmHg, with a systolic blood pressure target of 130 mmHg and lower, if tolerated. In those with established CVD or diabetic nephropathy, systolic blood pressure targets below 130 mmHg should be pursued. Initial pharmacotherapy should consist of a renin-angiotensin-aldosterone system inhibitor. There is an urgent need for good quality data regarding proper antihypertensive treatment initiation, optimal BP targets and optimal antihypertensive treatment for better clinical outcomes.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 1 / Hipertensão / Anti-Hipertensivos Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Revista: Expert Opin Pharmacother Assunto da revista: FARMACOLOGIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Grécia

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 1 / Hipertensão / Anti-Hipertensivos Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Revista: Expert Opin Pharmacother Assunto da revista: FARMACOLOGIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Grécia